Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2007 2
2013 1
2014 1
2015 3
2016 3
2017 2
2018 3
2019 1
2020 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration.
Linde L, Ørnbjerg LM, Rasmussen SH, Love TJ, Loft AG, Závada J, Vencovský J, Laas K, Nordstrom D, Sokka-Isler T, Gudbjornsson B, Gröndal G, Iannone F, Ramonda R, Hellamand P, Kristianslund EK, Kvien TK, Rodrigues AM, Santos MJ, Codreanu C, Rotar Z, Tomšič M, Castrejon I, Díaz-Gonzáles F, Di Giuseppe D, Ljung L, Nissen MJ, Ciurea A, Macfarlane GJ, Heddle M, Glintborg B, Østergaard M, Hetland ML. Linde L, et al. Arthritis Res Ther. 2023 Oct 19;25(1):205. doi: 10.1186/s13075-023-03184-7. Arthritis Res Ther. 2023. PMID: 37858143 Free PMC article.
Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. ...
Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-react …
Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible.
Kvien TK, Uhlig T, Kristiansen IS. Kvien TK, et al. Drugs. 2001;61(12):1711-20. doi: 10.2165/00003495-200161120-00003. Drugs. 2001. PMID: 11693461 Review.
Disease activity criteria were set to 28-swollen joint count (28-SJC) > or = 6, 28-tender joint count > or = 6, and erythrocyte sedimentation rate (ESR) > or = 28 mm/hour or C-reactive protein (CRP) > or = 20 mg/L. Sensitivity analyses were performed varying so …
Disease activity criteria were set to 28-swollen joint count (28-SJC) > or = 6, 28-tender joint count > or = 6, and erythrocyte sedime …
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. Paul S, et al. Clin Transl Sci. 2020 Jul;13(4):743-751. doi: 10.1111/cts.12760. Epub 2020 Apr 1. Clin Transl Sci. 2020. PMID: 32100960 Free PMC article.

Clinical outcomes of low disease activity (LDA) and remission were defined as Disease Activity Score in 28 joints with C-reactive protein (DAS28(CRP)) 2.7 and < 2.3, respectively. Quartile analysis results indicated that there may be an exposure-response relationship be

…
Clinical outcomes of low disease activity (LDA) and remission were defined as Disease Activity Score in 28 joints with C-reactive pro …
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.
Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordström D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernández MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R. Chatzidionysiou K, et al. J Rheumatol. 2017 Feb;44(2):162-169. doi: 10.3899/jrheum.160460. Epub 2017 Jan 15. J Rheumatol. 2017. PMID: 28089978
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
Georgiadis S, Ørnbjerg LM, Michelsen B, Kvien TK, Di Giuseppe D, Wallman JK, Závada J, Provan SA, Kristianslund EK, Rodrigues AM, Santos MJ, Rotar Ž, Pirkmajer KP, Nordström D, Macfarlane GJ, Jones GT, van der Horst-Bruinsma I, Hellamand P, Østergaard M, Hetland ML. Georgiadis S, et al. J Rheumatol. 2024 Jul 1;51(7):673-677. doi: 10.3899/jrheum.2023-1217. J Rheumatol. 2024. PMID: 38621792 Free article.
OBJECTIVE: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). ...
OBJECTIVE: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on e …
20 results